GlassScriptPhysician profile
Ryan D English
NPI 1518317585
$1,920.23
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $807 · 2022: $446 · 2023: $320 · 2024: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $427.95 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $231.99 | 2023-2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.93 | 2021 | |
| Astellas Pharma US INC | $166.45 | 2021-2022 | |
| Edwards Lifesciences Corporation | $157.36 | 2024 | Sapien 3 Ultra Resilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.48 | 2021 | |
| Shionogi INC | $145.79 | 2022-2024 | Fetroja |
| Neurocrine Biosciences, INC. | $120.00 | 2023 | |
| Incyte Corporation | $119.25 | 2021-2022 | |
| Glaxosmithkline, LLC. | $73.98 | 2023 | Bexsero |
| Aroa Biosurgery Incorporated | $43.46 | 2024 | |
| Merck Sharp & Dohme LLC | $42.46 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $34.91 | 2021 | |
| Pfizer INC. | $18.21 | 2023 | |
| Csl Behring | $17.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan English listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.